Switzerland’s biotech hub - a powerful source of innovation

AFSSI Connexions, Convention 2019, July 2nd, Lyon

Michael Altorfer

CEO, Swiss Biotech Association

The Swiss biotech industry is a key asset

Switzerland is one of the best

and most innovative locations

for biotechnology in Europe and

the world

Local companies hold

leading positions throughout many

sectors and thus attract capital and

researchers from all over the world

The basis for this success is a

close-knit network between

research and development, driven

by renowned universities, highly

specialized SMEs and strong

multinational corporations

In addition to being an attractive

place to live for international

specialists, Switzerland also offers a

modern infrastructure, a

beneficial funding environment

and access to a highly-qualified

workforce

swissbiotech.org2

A tight cross-functional network

Cell culture

Engineering

Analytical

Bio-IT

CMO

R&D

Biotech consulting

Non-biotech consulting

Chemicals reagents

Labware

Bio-equipment

Agriculture

Diagnostics

Medtech

Food & industrial

Veterinary

Therapeutics

SBA member

company activities

swissbiotech.org3

Swiss Biotech: Structural changes offer new investment

and partnering opportunities

SBA member

company activities

CMOs take over production sites

CRO share research risk

Clinical trials are outsourced

and even financed by partners

Biotech companies stay independent:

• build their commercial

organizations

• partner with distributors

team up with partners

that have access to

patients

• combine drug and

medical device or

service provider

Investors go it alone, build

virtual project teams rather

than companies

Service providers start

sharing risks and benefit

Some Biotech companies are

fully financed, eliminating the

need for small incremental financing

rounds

Business models not relying

on product development

swissbiotech.org4

Capital investment in Swiss biotech companies

5 Swiss Biotech Day 2019

From 2007 - 2018 Venture Kick invested CHF 3.16 million in 48

Swiss biotech startups. This amount was amplified 159 fold by

grants and VC investments.

6 Swiss Biotech Day 2019

2.0

1.8

1.6

1.4

1.2

1.0

0.8

0.6

0.4

Ma

rke

t co

ve

rag

e

0.6 0.8 1.2 1.4 1.6 1.8 2.0 2.2 2.61.0 2.4

Technology relevance

Bubble size represents the

number of active patents per

country of inventor origin,

reporting year 2016

High impact patents reflect innovation power

USA

France

Australia

Canada

Germany

NetherlandsUK

Denmark

Japan

China

South Korea

Russia

Switzerland

Source: IPI, Swiss Biotech Report 2017 swissbiotech.org7

Major investments in biopharmaceutical production sites

Novartis, 2020

EUR 100 million

Ciba-Geigy,

1996

Roche, 2007

CHF 400 million

MSD (former Werthenstein)

2015, 2008, 2000

MSD (former Werthenstein)

2015, 2008, 2000

UCB Pharma, 2007

CHF 400 million

Ferring, 2001

CHF 30 million

Serono, 1999

EUR 300 million

Lonza, 2020

CHF 290 million

CSL Behring, 2020

CHF 1 billion

Biogen, 2019

CHF 1.5 billion

Cerbios, 2013

SBA, Swiss Biotech Report 2018

Significant and growing export factor

swissbiotech.org9

Swiss Biotech industry in numbers

swissbiotech.org11

Global talent competitiveness

50

55

60

65

70

75

Sco

re

1 2

RankingX

18 16 8 9 24 17 12 40 7 11 10 31 35 5 3 13 25 4 6

Source: Instead, GTCI Report 2017

1 Nation - 1 Biotech Cluster

A world-leading Biotech hub

• Attractive and reliable framework conditions

• Stable political environment

• Strong intellectual property protection

• Renowned universities

• Highly-qualified workforce

• Excellent R&D infrastructure

• Beneficial funding environment

• Superb quality of life

swissbiotech.org13

Swiss Biotech Association

The central resource for the Swiss biotech industry

3M • Abologix • AC Bioscience • AC Immune • Activen • ADC Therapeutics • Addex Therapeutics • Adolf Kuhner • Agidens • Alphastrat • AlveoliX • Amal Therapeutics • Anaveon • Anergis • Anjarium Biosciences •

Asceneuron • Assystem Care • Aurealis Pharma • Axon Lab • B3C Group • Baccinex • Bachem • Baliopharm • Basilea Pharmaceutica • BC Platforms • Becton Dickinson • Bench • Bideco • Bio Innovations • BioConcept

• Bioengineering • Biogen • BioLingus • Biomapas • Biopole • Bio-Rad • Biosynth • Bio- Technopark Schlieren-Zurich • BioVersys • blsc • Bucher Biotec • Buchi • BUHLMANN • Cabinet Prive de Conseils • Calypso

Biotech • Canlion • Carbogen Amcis • CarthaGenetics • C-CIT Sensors • CDR-Life • CEBIS International • Celerion • Cell Medica • Cellestia Biotech • Cerbios-Pharma • certus molecular diagnostics • Chemgineering

Technology • Cilatus Biopharma Consulting • CimArk • CIS Pharma • Clinipace • Consultants in Science • Coulter & Partners • CRB • Creoptix • CSL Behring • CTC Clinical Trial Consulting • Culture Collection of

Switzerland • Curatis • Debiopharm International • DXC RT • EffRx Pharmaceuticals • Elanix Biotechnologies • Elthera • Eurofins Medical Device Testing • EVA • Evitria • ExcellGene • ExpertInova • Finox Biotech •

Future Health Pharma • Gain Therapeutics • GBiotech • GE Healthcare • Geistlich Pharma • Gene Signal • Genedata • GeNeuro • Genkyotex • Glenmark Pharmaceuticals • GMT Fine Chemicals • Healthcare Impact

Foundation • Hemex • Heptares Therapeutics • HGF • Homburger • Humabs BioMed • IBR • ICON Clinical Research • Idorsia Pharmaceuticals • IE Life Science Engineering • Incyte Biosciences International •

Inflamalps • Infors • InnoMedica • Inofea • Inositec • InSphero • Integra Biosciences • InterAx Biotech • Janssen-Cilag • Jenal & Partners Biosafety Consulting • Jung & Partners • KPMG • Labatec Pharma • Laves-

Arzneimittel • LeadXpro • LimmaTech Biologics • Lipidon • Lonza • Loroch • LubioScience • Lunaphore Technologies • LYO-X • Malcisbo • Marsa Corporate Finance • Maxia Strategies • MD Biosciences • Med

Discovery • Mediatum • Memo Therapeutics • Merck & Cie • MetrioPharm • Micro-Sphere • Microsynth • Molecular Partners • Morgan Sindall • Mymetics • NBE-Therapeutics • NDA • Neurimmune • Novartis Pharma •

NovImmune • Numab • ObsEva • Oculis • OLS • Omya • Onelife • P & G MedChem • Pall • PAREXEL • Phargentis • Philip Morris International • Philochem • Phoenixus Pharmaceuticals • PIQUR • PolyGene •

Polyneuron • Polyphor • Preclin Biosystems • PreComb Therapeutics • Promega • ProteoMediX • PSI CRO • Quotient Suisse • Recordati • Redbiotec • RegenLab • regulanet • ReseaChem • Roche Glycart • SAKK •

Santhera • Sartorius • Schmidt Versicherungs Treuhand • Seagen International • Securecell • Selexis • Servier • SFL Pharma • SGS M-Scan • Shimadzu • SimplicityBio • Socorex • SOPHiA GENETICS • SpacePharma

• Dr. Rudolf K.Sprungli • Strekin • SunRegen Healthcare • Swiss Institute for Regenerative Medicine • Swissfillon • Switzerland Global Enterprise • SynDermix • Syngenta • Synlab • Synple Chem • T3 Pharma •

Talentmark • Target BioScience • tepthera • the RSA Group • Therachon • Thermo Fisher Life Technologies • Thermo Fisher Scientific Prionics • Tigermed • Tillotts Pharma • tiventa • TJM Conseils • Tolerys •

TOLREMO therapeutics • Toolpoint for Lab Science • Topadur • Triplan Ingenieur • UCB • Unitectra • ValuationLab • Vaxxilon • Venture Valuation • Versameb • Versantis • Virometix • Voisin Consulting Life Sciences •

MSD Werthenstein BioPharma • Wyss Zurich

swissbiotech.org15

Members of the Swiss Biotech Association (255)

Our mission

swissbiotech.org16

Developing favorable and

competitive framework

conditions

Attracting talent, know-how and

financial resources to drive

innovation and growth

Technology transfer

Academia – Industry

collaborationsTaxation

Seed / venture

capital

Clinical

developments

Industry – Hospital

collaborations

Swiss Biotech Association

Improving framework conditions

swissbiotech.org17

Promotion support

Biotech directory,

jobs, clinical pipeline

SBA Academy

Seminars

Workshops

Discounted business

offerings (e.g.

pension fund)

Co-promotions

Discounted access

Speaker

opportunities

Swiss Biotech Association

Business solutions

swissbiotech.org18

swissbiotech.org19

Our mission

Promoting the

accomplishments of the

Swiss biotech industry

Fostering networking through

strategic, national and

international partnerships

Developing favorable and

competitive framework

conditions

Attracting talent, know-how and

financial resources to drive

innovation and growth

The Swiss Biotech DirectoryFinding the right partner – Switzerland's most comprehensive database

www.swissbiotech.org/companies/

swissbiotech.org20

The Swiss Biotech Association has launched Swiss Biotech Success Stories to

celebrate those who have made significant contributions to the industry

Dedicated to scientists, pioneers, entrepreneurs, innovators and supporters who led

the way, opened the horizon and prepared the ground for lasting achievements

Swiss Biotech Success Stories accentuate past industry highlights and act as

motivator for future achievements

Celebrating and honoring major achievements

General Assembly,

May 7, 2019

swissbiotech.org23

Award winner 2019

Launched the Swiss Biotech Success Stories Award

The first awards went to:

• Biogen

• Okairos

• Roche Glycart

• Selexis

• Vifor Fresenius Renal Medical Care Pharma

swissbiotech.org34

National biotech convention: Swiss Biotech Day in Basel

> 850 participants (plus 30%)

42 exhibitors (plus 55%)

38% participants from abroad (plus 5%)

1st year of success story award

906 organizations in

Swiss Biotech Directory (plus 35%)

47 new members of the

Swiss Biotech Association (plus 25%)

> 30 co-promotion partner

(plus 200%)

2019 Swiss Biotech

Report